Race Reporting in GU Cancers Indicates Relative Overrepresentation of White Individuals
Lythgoe et al studied patterns of race reporting in genitourinary (GU)
cancer trials.
Diagnosis & Disease Information
Radium-223/Enzalutamide Combination Therapy Could Improve Outcomes in Progressive mCRPC
Kessel et al present the final efficacy and safety results from a phase 2 study of radium-223 plus enzalutamide vs enzalutamide monotherapy in metastatic castration-resistant prostate cancer (mCRPC).
Final Analysis of ARAMIS Trial Confirms Significant OS Benefit With Darolutamide in nmCRPC
Sensitivity analyses were performed to assess the effect of placebo to darolutamide crossover on overall survival benefit among ARAMIS trial participants.
Bone-Targeted Therapies and Incidence of Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma
A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC and bone-targeted therapies for bone metastases.
Depression Common After Prostate Cancer Diagnosis, Incidence Higher in Black Men
Retrospective study of more than 32,000 veterans sought to determine the incidence, management, and mortality of men with prostate cancer who experience depression.
Effect of Hypertension History on Outcomes in Patients With Metastatic Renal Cell Carcinoma
A retrospective analysis sought to determine the effect of hypertension on overall survival, response, and progression-free survival in patients with mRCC.
Noncompletion Rates of SBRT Compared With Conventional Fractionation in Radiotherapy for Localized Prostate Cancer
Data analysis evaluated the associations between rates of treatment noncompletion and radiotherapy fractionation schedules for men with localized prostate cancer.
Active Surveillance Appropriate for Favorable Intermediate-Risk PCa
Active surveillance may help many men with favorable intermediate-risk prostate cancer to avoid the adverse effects of treatment for 5 years.
NLR Rise May Predict Mortality, Treatment Failure Risks in mRCC
A rise in neutrophil-to-lymphocyte ratio of 3 or more after 2 months of therapy is associated with an increased risk for death in less than 1 year and treatment failure in less than 6 months, according to investigators.
Radiation Therapy Increases Survival in Metastatic Urothelial Carcinoma
Patients with metastatic urothelial carcinoma have significantly longer overall survival when treated with a combination of radiotherapy and chemotherapy compared with chemotherapy alone, a study found.
- Loading...
Loading...
Next post in Bladder Cancer
Loading... 
Loading...